SUVENHealthcare Research, Analytics & Technology
Suven Life Sciences Ltd — Cash Flow Statement
₹131.70
-2.75%
Suven Life Sciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -191.38 Cr | -82.62 Cr | -118.88 Cr | -147.31 Cr | — |
| Capital Expenditure | -37.28 Cr | — | -2.89 Cr | -19.77 Cr | -6.30 Cr |
| End Cash Position | 15.03 Cr | 14.93 Cr | 37.02 Cr | 5.27 Cr | — |
| Beginning Cash Position | 14.93 Cr | 37.02 Cr | 5.27 Cr | 9.35 Cr | — |
| Changes In Cash | 0.09 Cr | -22.09 Cr | 31.75 Cr | -4.07 Cr | — |
| Financing Cash Flow | -0.76 Cr | -1.05 Cr | 395.54 Cr | 145.69 Cr | — |
| Interest Paid Cff | -0.05 Cr | -0.16 Cr | -0.26 Cr | -0.40 Cr | — |
| Investing Cash Flow | 154.95 Cr | 61.59 Cr | -247.81 Cr | -22.23 Cr | — |
| Net Other Investing Changes | 125.82 Cr | -1.93 Cr | -147.17 Cr | -0.30 Cr | — |
| Interest Received Cfi | 5.68 Cr | -16.43 Cr | 6.42 Cr | 1.12 Cr | — |
| Net Investment Purchase And Sale | 60.72 Cr | 77.52 Cr | -104.17 Cr | -44.72 Cr | — |
| Net PPE Purchase And Sale | -37.28 Cr | 2.42 Cr | -2.89 Cr | -19.77 Cr | — |
| Purchase Of PPE | -37.28 Cr | — | -2.89 Cr | -19.77 Cr | -6.30 Cr |
| Operating Cash Flow | -154.10 Cr | -82.62 Cr | -115.98 Cr | -127.54 Cr | — |
| Taxes Refund Paid | 0.61 Cr | 6.18 Cr | -1.10 Cr | -0.52 Cr | — |
| Change In Working Capital | 10.07 Cr | 6.89 Cr | 11.48 Cr | -3.93 Cr | — |
| Change In Other Current Liabilities | 7.00 Cr | 2.21 Cr | 3.58 Cr | -6.47 Cr | — |
| Change In Other Current Assets | -1.34 Cr | 5.97 Cr | 7.50 Cr | 2.74 Cr | — |
| Change In Payable | 3.16 Cr | 0.40 Cr | -0.32 Cr | -1.01 Cr | — |
| Change In Inventory | 0.47 Cr | -0.71 Cr | 0.02 Cr | 0.12 Cr | — |
| Change In Receivables | -0.05 Cr | -0.48 Cr | 0.49 Cr | 0.46 Cr | — |
| Other Non Cash Items | -5.64 Cr | 9.13 Cr | -12.13 Cr | -4.30 Cr | — |
| Stock Based Compensation | 1.27 Cr | 0.00 | — | — | — |
| Depreciation And Amortization | 5.31 Cr | 5.82 Cr | 5.83 Cr | 3.56 Cr | — |
| Depreciation | 5.31 Cr | 5.82 Cr | 5.83 Cr | 3.56 Cr | — |
| Gain Loss On Investment Securities | -4.98 Cr | -4.55 Cr | -1.79 Cr | -0.36 Cr | — |
| Net Income From Continuing Operations | -160.75 Cr | -106.08 Cr | -118.27 Cr | -122.00 Cr | — |
| Issuance Of Capital Stock | — | 0.00 | 397.40 Cr | 147.64 Cr | 36.92 Cr |
| Net Common Stock Issuance | — | 0.00 | 397.40 Cr | 147.64 Cr | 36.92 Cr |
| Common Stock Issuance | — | 0.00 | 397.40 Cr | 147.64 Cr | 36.92 Cr |
| Net Issuance Payments Of Debt | — | 0.00 | -0.48 Cr | -0.85 Cr | -0.69 Cr |
| Net Long Term Debt Issuance | — | 0.00 | -0.48 Cr | -0.85 Cr | -0.69 Cr |
| Sale Of PPE | — | 2.42 Cr | — | — | — |
| Other Cash Adjustment Outside Changein Cash | — | — | 1000.00 | — | 1000.00 |
| Net Short Term Debt Issuance | — | — | -0.48 Cr | -0.85 Cr | — |
| Sale Of Investment | — | — | 0.61 Cr | 41.45 Cr | 91.86 Cr |
| Purchase Of Investment | — | — | -104.78 Cr | -44.72 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Suven Life Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.